Research progress of the SLFN family in malignant tumors

被引:0
|
作者
Yu, Jiale [1 ,2 ]
Guo, Zhijuan [3 ,4 ]
Zhang, Junyi [2 ]
机构
[1] Inner Mongolia Med Univ, Hohhot, Peoples R China
[2] Chifeng Univ, Sch Basic Med, Chifeng, Peoples R China
[3] Peking Univ, Canc Hosp, Dept Pathol, Hohhot, Peoples R China
[4] Inner Mongolia Med Univ, Affiliated Canc Hosp, Hohhot, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
SLFN; tumors; immune infiltration; therapy; immunosuppression; SCHLAFEN; TRANSCRIPTION; EXPRESSION; GENES;
D O I
10.3389/fonc.2024.1468484
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Schlafen (SLFN) gene family has emerged as a critical subject of study in recent years, given its involvement in an array of cellular functions such as proliferation, differentiation, immune responses, viral infection inhibition, and DNA replication. Additionally, SLFN genes are linked to chemosensitivity, playing a pivotal role in treating malignant tumors. Human SLFNs comprise three domains: the N-terminal, middle (M), and C-terminal. The N- and C-terminal domains demonstrate nuclease and helicase/ATPase activities, respectively. Meanwhile, the M-domain likely functions as a linker that connects the enzymatic domains of the N- and C-terminals and may engage in interactions with other proteins. This paper aims to present a comprehensive overview of the SLFN family's structure and sequence, examine its significance in various tumors, and explore its connection with immune infiltrating cells and immune checkpoints. The objective is to assess the potential of SLFNs as vital targets in cancer therapy and propose novel strategies for combined treatment approaches.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Research progress of TRIMs protein family in tumors
    Huang, Yuanyuan
    Wu, Hongwei
    Liu, Ruyuan
    Jin, Song
    Xiang, Weilai
    Yang, Chang
    Xu, Li
    Zhu, Xiaonian
    BIOCELL, 2023, 47 (03) : 445 - 454
  • [2] Research progress on ADAM28 in malignant tumors
    Lanlan Zhao
    Wei Liu
    Fei Wang
    Discover Oncology, 16 (1)
  • [3] Research progress of biomineralization for the diagnosis and treatment of malignant tumors
    Wu, Yulu
    Pan, Xun
    Xie, Huixu
    Que, Lin
    Tang, Xiufa
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [4] Research progress on GP73 in malignant tumors
    Liang, Rong
    Liu, Ziyu
    Piao, Xuemin
    Zuo, Mingtang
    Zhang, Jinyan
    Liu, Zhihui
    Li, Yongqiang
    Lin, Yan
    ONCOTARGETS AND THERAPY, 2018, 11 : 7417 - 7421
  • [5] Clinical research progress of fruquintinib in the treatment of malignant tumors
    Zhao, Shihao
    Wang, Wenhui
    Li, Jingyi
    Li, Zhigang
    Liu, Zhanbo
    Zhang, Shunchao
    Chen, Zhaoqi
    Wang, Hongling
    Wang, Xiangqi
    Wang, Juntao
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (06) : 612 - 622
  • [6] The Research Progress of Metformin Regulation of Metabolic Reprogramming in Malignant Tumors
    Sui, Qihai
    Yang, Huiqiang
    Hu, Zhengyang
    Jin, Xing
    Chen, Zhencong
    Jiang, Wei
    Sun, Fenghao
    PHARMACEUTICAL RESEARCH, 2024, 41 (11) : 2143 - 2159
  • [7] Research progress on venous thrombosis development in patients with malignant tumors
    Wang, Teng-Fei
    Chen, Qian
    Deng, Jie
    Li, Shi-Liang
    Xu, Yuan
    Ma, Si-Xing
    WORLD JOURNAL OF CLINICAL CASES, 2024, 12 (11)
  • [8] Research progress of Bub3 gene in malignant tumors
    Wang, Chenyang
    Cheng, Dating
    Pan, Chenglong
    Wang, Chunyan
    Nie, Zhi
    CELL BIOLOGY INTERNATIONAL, 2022, 46 (05) : 673 - 682
  • [9] Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment
    Shijing You
    Xiahui Han
    Yuance Xu
    Qin Yao
    Amino Acids, 2023, 55 : 1213 - 1222
  • [10] Research progress on the role of cationic amino acid transporter (CAT) family members in malignant tumors and immune microenvironment
    You, Shijing
    Han, Xiahui
    Xu, Yuance
    Yao, Qin
    AMINO ACIDS, 2023, 55 (10) : 1213 - 1222